Kalaris Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 2.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 48.32M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeut...